Sionna Therapeutics (SION) Change in Accured Expenses (2024 - 2026)

Sionna Therapeutics has disclosed Change in Accured Expenses across 3 years of filings, most recently posting -$3.5 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$3.5 million, up 19.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (up 558.25% YoY), and the FY2025 annual result was $2.0 million, up 82.87% from the prior year.
• Change in Accured Expenses came in at -$3.5 million for Q1 2026 at Sionna Therapeutics, down from $2.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.2 million in Q4 2024 to a low of -$4.3 million in Q1 2025.
• The 3-year median for Change in Accured Expenses is $1.4 million (2024), against an average of -$45333.3.
• Peak annual rise in Change in Accured Expenses reached 344.69% in 2025, while the deepest fall reached 64.76% in 2025.
• Sionna Therapeutics' Change in Accured Expenses stood at $3.2 million in 2024, then declined by 21.49% to $2.5 million in 2025, then slumped by 238.96% to -$3.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.5 million (Q1 2026), $2.5 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.